With a market capitalization (market cap) of $1.72B — a measure of how much the company is worth — Avalyn Pharma Inc. Common Stock is the 2209th most valuable company in Healthcare as of August 19, 2026. Shares trade at $38.86, up +1.59% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Visit websiteAs of August 19, 2026, Avalyn Pharma Inc. Common Stock (AVLN) is worth $1.72B — this is its market capitalization, the total value of all its outstanding shares.
Avalyn Pharma Inc. Common Stock’s market cap is $1.72B, which ranks it #2209 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Avalyn Pharma Inc. Common Stock (AVLN) shares trade at $38.86, up 1.59% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025